Maria Fardis ends a two-year CEO hia­tus; More lead­er­ship turnover on the menu at Gala­pa­gos

→ Fol­low­ing her res­ig­na­tion from Io­vance, Maria Fardis piv­ot­ed to Fra­zier Life Sci­ences as a ven­ture part­ner. But she’s back in the sad­dle at a Fra­zier up­start, tak­ing over for Mark Bar­rett as CEO of San Diego-based IL-11 biotech Lassen Ther­a­peu­tics. Fardis al­so chairs the board at Ob­sid­i­an Ther­a­peu­tics and has a board seat at CRISPR Ther­a­peu­tics.

CMC-re­lat­ed de­lays ham­pered po­ten­cy as­says for Io­vance’s tu­mor in­fil­trat­ing lym­pho­cyte ther­a­py li­fileu­cel, and Fardis stepped down not even 24 hours af­ter the BLA for li­fileu­cel stalled out again in 2021. To this day, a per­ma­nent re­place­ment for in­ter­im chief and gen­er­al coun­sel Fred­er­ick Vogt hasn’t been named.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN